Financial Survey: Coloplast A/S (OTCMKTS:CLPBF) vs. Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH – Get Free Report) and Coloplast A/S (OTCMKTS:CLPBF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Earnings & Valuation

This table compares Nyxoah and Coloplast A/S”s revenue, earnings per share and valuation.

Coloplast A/S has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Nyxoah and Coloplast A/S, as reported by MarketBeat.com.

Nyxoah presently has a consensus price target of $17.00, suggesting a potential upside of 78.38%. Given Nyxoah’s higher probable upside, equities analysts clearly believe Nyxoah is more favorable than Coloplast A/S.

Profitability

This table compares Nyxoah and Coloplast A/S’s net margins, return on equity and return on assets.

Institutional and Insider Ownership

15.1% of Coloplast A/S shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Coloplast A/S beats Nyxoah on 5 of the 8 factors compared between the two stocks.

About Nyxoah

(Get Free Report)

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Coloplast A/S

(Get Free Report)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.